Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Company Overview - Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity, aiming to help patients overcome serious illnesses through innovative scientific approaches targeting well-understood biological pathways [2] - The company's pipeline includes three key products: CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells; and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for obesity treatment [2] Upcoming Events - Yuval Cohen, Ph.D., CEO of Corbus, will provide a corporate update and engage in one-on-one investor meetings at the Jefferies Global Healthcare Conference scheduled for June 3-5, 2025, in New York [1] - The presentation by Corbus is set for June 4, 2025, at 4:55 p.m. ET [2]